STING1 and neoplasm: For example, encapsulating STING agonists within LNPs can increase their accumulation at the tumor site and enhance the production of type I interferons through activation of the STING pathway, thereby promoting an antitumor immune response (Khalifa et al., 2024; Nakamura et al., 2021; Qiu et al., 2024).